KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 0.59.

  • Halozyme Therapeutics' Asset Utilization Ratio rose 2117.84% to 0.59 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.59, marking a year-over-year increase of 2117.84%. This contributed to the annual value of 0.61 for FY2025, which is 1381.08% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Asset Utilization Ratio is 0.59, which was up 2117.84% from 0.58 recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Asset Utilization Ratio ranged from a high of 0.59 in Q4 2025 and a low of 0.32 during Q3 2022
  • Its 5-year average for Asset Utilization Ratio is 0.45, with a median of 0.43 in 2021.
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first soared by 3788.12% in 2021, then tumbled by 2394.29% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Asset Utilization Ratio stood at 0.39 in 2021, then decreased by 8.0% to 0.36 in 2022, then grew by 28.4% to 0.46 in 2023, then grew by 6.17% to 0.49 in 2024, then rose by 21.18% to 0.59 in 2025.
  • Its Asset Utilization Ratio stands at 0.59 for Q4 2025, versus 0.58 for Q3 2025 and 0.55 for Q2 2025.